Lactobacillus rhamnosus
Lactobacillus rhamnosus is a lactic-acid bacterium widely used in probiotic supplements and in some dairy fermentation. It is one of the most-studied probiotic species, but the trial evidence is for specific named strains at specific doses — not for the species as a generic category.
Camden Medicals editorial · Last reviewed 27 April 2026 · Next review April 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Probiotic
- Typical daily dose
- Most published trials use 10⁹ to 10¹¹ CFU per day (one to one hundred billion colony-forming units), often for 7 to 28 days for AAD prevention or for at least 4 weeks for IBS.
- Top use evidence
- Moderate
On this page
What it is
Lactobacillus rhamnosus is a Gram-positive, rod-shaped lactic-acid bacterium first isolated in the 1980s. Following the 2020 reclassification of the Lactobacillus genus (Zheng et al., IJSEM), the species was retained in the genus Lactobacillus alongside L. acidophilus, L. crispatus, and related organisms.
The most-studied strain in the species is Lactobacillus rhamnosus GG (LGG) — isolated by Sherwood Gorbach and Barry Goldin in 1985 and branded by Valio in Finland. It is the basis of dozens of clinical trials in antibiotic-associated diarrhoea, infant diarrhoea, and various other indications. Other commercially-supplied strains include L. rhamnosus HN001 (DSM Nutritional Products) and L. rhamnosus LC705 (Valio).
Each named strain has its own evidence base. A supplement labelled simply "Lactobacillus rhamnosus" without a strain identifier (or that identifies a strain without published clinical data) cannot inherit evidence generated for LGG or any other named strain.
At a glance
- A lactic-acid bacterium found in some fermented dairy and many probiotic supplements.
- Strain specificity matters: Lactobacillus rhamnosus GG, HN001, and LC705 are different organisms with different evidence.
- Best-evidenced clinical use: prevention of antibiotic-associated diarrhoea (AAD), with credible Cochrane evidence for specific strains.
- No GB-authorised health claim for "Lactobacillus rhamnosus" generically; specific claims rest on per-strain trial data and the EFSA on-hold botanical-claims framework does not apply (probiotics are evaluated separately).
- Caution in immunocompromised people, critically ill patients, infants in neonatal intensive care, and central-venous-catheter users — see safety section.
What people use it for
Adults starting a course of antibiotics
Specific strains (notably L. rhamnosus GG) have credible Cochrane evidence for reducing the risk of antibiotic-associated diarrhoea when started early in the antibiotic course. Discuss timing with your pharmacist; some guidance recommends taking the probiotic 2 hours apart from the antibiotic dose. [1]
Some evidenceModerateAdults experiencing antibiotic-associated diarrhoea symptoms
Some evidence that probiotics including L. rhamnosus GG reduce the duration of symptoms once they have started, though the prevention evidence is stronger than the treatment evidence. [1]
Some evidenceLimitedInfants with acute infectious diarrhoea (under specialist or GP supervision)
Earlier Cochrane evidence supported L. rhamnosus GG for shortening acute infectious diarrhoea in children. More recent large trials (Schnadower et al. NEJM 2018) have weakened this signal; clinical guidelines are evolving. Talk to your GP — do not self-administer to infants without GP advice with probiotics. [6]
Popular, not provenMixedPeople with irritable bowel syndrome (IBS)
Mixed evidence overall. Some trials with specific Lactobacillus strains show modest symptom improvement; the broader category claim is less supported. NICE CG61 lists probiotics as one option to try for at least four weeks. [3]
Some evidenceLimited
How it works
L. rhamnosus produces lactic acid as a primary fermentation end-product, lowering local gut pH and competing with potentially-pathogenic bacteria for binding sites on the intestinal epithelium. Specific strains also secrete antimicrobial peptides, modulate intestinal-barrier function, and influence local immune signalling — but the strength of these effects is strain-specific.
Like most probiotic bacteria, L. rhamnosus is not believed to permanently colonise the adult human gut; the effect lasts as long as the supplementation continues, with measurable bacterial counts in stool falling away within days to weeks of stopping the supplement.
Common myths
Myth""Probiotic" on a label means clinical evidence applies"
RealityIt does not. The clinical evidence for "L. rhamnosus" is almost entirely for specific named strains (most often GG) at specific doses (typically 10⁹ to 10¹¹ CFU/day). A supplement that simply lists "L. rhamnosus" without a strain identifier and a CFU count per dose has not, by labelling alone, demonstrated equivalence to the trial evidence.
Myth"More CFU is always better"
RealityUp to a point. The Cochrane AAD review found a dose-response relationship up to roughly 5 × 10⁹ CFU/day, beyond which extra does not appear to add benefit. Megadoses (10¹² CFU and up) have no published evidence of additional benefit and add no clear value beyond what the cited trials studied. [1]
Myth"L. rhamnosus permanently colonises the gut after a course"
RealityIt does not, in adults. Stool counts fall away within days to weeks of stopping supplementation. The effect is "as long as you take it"; there is no compelling evidence of lasting colonisation in the adult gut from supplementation alone.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Lactobacillus rhamnosus. Each answer is editorial and links to its evidence in the Sources list below.
Should I take a probiotic with my antibiotic?
For specific clinical situations (high risk of C. difficile, history of severe AAD, broad-spectrum antibiotic course), there is moderate-quality Cochrane evidence supporting probiotic co-administration. Talk to your pharmacist about whether it is right for your specific antibiotic course, your medical history, and the timing (some guidance recommends spacing the probiotic and antibiotic doses by at least 2 hours). [1]
Does Lactobacillus rhamnosus GG help with IBS?
Evidence is limited but it is one option among several listed in NICE CG61. If you trial a probiotic for IBS, NICE recommends sticking with one product for at least four weeks at the manufacturer-recommended dose before judging whether it works. Talk to your GP about whether it fits your wider IBS management plan. [3]
Is it safe for everyone to take a probiotic?
For most healthy adults, yes — at typical food-supplement doses, L. rhamnosus has a long safety record. But probiotics are NOT for everyone in every situation: people who are immunocompromised, critically ill, in intensive care, have central venous catheters, or have severe acute pancreatitis are at small but real risk of bacteraemia or fungaemia from probiotic organisms reaching the bloodstream. If any of those apply, talk to your specialist.
Will L. rhamnosus survive my stomach acid?
Some of it will, some of it won''t — exact survival depends on formulation (capsule type, enteric coating, freeze-drying method) and on whether it is taken with food. The trials that report clinical benefit measured outcomes, not stomach-survival rates; if a specific strain at a specific dose has trial evidence, that evidence already accounts for whatever survives in practice.
Should I take a probiotic when I am healthy and well?
Routine probiotic supplementation in healthy adults without a specific indication has limited evidence. The most consistent evidence for general gut-microbiome health is dietary: a varied plant-fibre intake, regular fermented foods, and avoiding unnecessary antibiotics. See the gut microbiome explainer for more detail.
Are dairy-free probiotic supplements as good as the dairy-grown ones?
For the same strain at the same delivered dose, yes. The growth medium used during manufacture does not change the bacterium itself. Dairy-free formulations are appropriate for vegan, vegetarian, and lactose-intolerant consumers and should be labelled as such.
Camden guides citing Lactobacillus rhamnosus
Editorial pieces from the Camden blog that reference Lactobacillus rhamnosus. Each guide cites the evidence it draws on.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Antibiotic-associated diarrhoea (AAD) prevention in adults and children
ModerateEvidencemoderateThe Cochrane review (Guo et al., CD004827.pub5, 2019) of probiotics for AAD prevention found moderate-quality evidence that probiotics — including L. rhamnosus GG — reduce the risk of AAD, with a number needed (NNT) in the region of 1 in 10 to 1 in 13. The effect was strongest with higher doses (≥5 × 10⁹ CFU/day) and when started within 2 days of antibiotic initiation. [1]
Clostridioides difficile-associated diarrhoea prevention
ModerateEvidencemoderateThe Cochrane review (Goldenberg et al., CD006095, 2017) found moderate-quality evidence that probiotics — particularly higher-dose regimens started early — reduce the risk of C. difficile-associated diarrhoea in patients receiving antibiotics. L. rhamnosus is among the strains studied, alongside Saccharomyces boulardii. [2]
Acute infectious diarrhoea in children
MixedEvidencemixedEarlier meta-analyses supported L. rhamnosus GG for shortening acute paediatric diarrhoea by approximately one day. The 2018 Schnadower NEJM trial (N=971, US emergency departments) and the Freedman PROGUT trial (Canada) both found NO benefit. Clinical guidance has shifted toward more cautious framing. [6]
IBS symptom management
LimitedEvidencelimitedProbiotics, including some L. rhamnosus formulations, are listed in NICE CG61 as one option for IBS. The evidence is limited and strain-specific; trials longer than 12 weeks are scarce. [3]
Safety
Lactobacillus rhamnosus has a long safety record at typical food-supplement doses for most healthy adults. It is NOT appropriate for everyone — see the scenarios below.
Talk to your pharmacist or GP first if you:
- You are immunocompromised, on chemotherapy, or have HIV with a low CD4 count.
- You are critically ill, in intensive care, or have a central venous catheter (rare reports of probiotic bacteraemia in these settings).
- You have severe acute pancreatitis (a 2008 Dutch trial reported increased mortality with a multi-strain probiotic in this specific population).
- You are buying for a premature or unwell newborn — neonatal probiotics need specialist supervision.
- You are pregnant or breastfeeding.
- You are starting a course of antibiotics — your pharmacist can advise on whether and how to combine.
Common side effects: Mild bloating or wind in the first few days; settles with continued use. Rare in healthy adults.
Pregnancy and breastfeeding
L. rhamnosus has been used in pregnancy in some research contexts (e.g. allergy-prevention trials in late pregnancy and in infants). For routine use in pregnancy, talk to your midwife or pharmacist. The substance itself has a generally favourable safety profile, but pregnancy should always be discussed before starting any supplement.
Used in some research contexts during breastfeeding. Talk to your pharmacist or GP.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Severe immunocompromise (active leukaemia / lymphoma, post-transplant, low CD4 HIV, high-dose chemotherapy) — discuss with specialist before use.
- Critical illness with central venous access.
- Severe acute pancreatitis (Besselink Lancet 2008 — caution applies to probiotic mixtures generally).
Drug interactions
- Antibiotics — co-administered probiotics should typically be spaced by at least 2 hours; the probiotic itself is not destroyed by the antibiotic but absorption / colonisation is reduced when taken simultaneously.
- Immunosuppressants — caution as for the contraindications above.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild bloating or flatulence, especially in the first 1-2 weeks; usually settles with continued use.
Rare side effects
- Bacteraemia (probiotic organism in the bloodstream) — rare; almost exclusively reported in immunocompromised or critically-ill patients.
- Allergic reactions to dairy-grown formulations in dairy-allergic individuals (the bacterium itself is not the allergen; residual milk protein in the formulation is).
How to take it
- Typical supplemental range
- Most published trials use 10⁹ to 10¹¹ CFU per day (one to one hundred billion colony-forming units), often for 7 to 28 days for AAD prevention or for at least 4 weeks for IBS.
- Timing
- For antibiotic co-administration, some guidance recommends spacing the probiotic and antibiotic doses by at least 2 hours.
How to spot quality
Look for
- Named strain identifier on the label (e.g. "Lactobacillus rhamnosus GG", "L. rhamnosus HN001"), not just the species name.
- Stated CFU per recommended daily dose AT END OF SHELF LIFE (not at manufacture).
- GMP-certified manufacture; cold-chain handling where relevant.
- Vegan / vegetarian / dairy-free declaration where applicable.
Red flags
- Generic "probiotic blend" with no per-strain CFU breakdown.
- "Strain identifier omitted" — usually a sign that the strain has no published clinical evidence to point at.
- CFU stated only at manufacture (which usually overstates what reaches the consumer).
- Marketing claims about immunity, mood, or weight loss that go beyond authorised UK health claims.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Saccharomyces boulardii
Moderate evidenceL. rhamnosus GG and S. boulardii dominate the AAD-prevention literature; combining them is common practice in multi-strain products.
Antibiotic-associated diarrhoea (AAD) is driven by gut-microbiome disruption. Saccharomyces boulardii (a non-pathogenic yeast) acts independently of antibiotics (no bacterial-antibiotic-killing effect), produces protease that cleaves Clostridioides difficile toxin A, and competes with pathogens for adhesion sites. Lactobacillus rhamnosus GG (a bacterial probiotic) competes for adhesion sites, produces antimicrobial peptides and short-chain fatty acids, and modulates gut immune signalling. The species are non-redundant in mechanism and can be combined.
Evidence: Goldenberg 2017 Cochrane review (Cochrane Database Syst Rev 12:CD006095) of 39 RCTs with 9,955 participants found probiotics reduce C. difficile-associated diarrhoea by 60% (NNT 42 overall, NNT 12 in high-baseline-risk patients). S. boulardii and L. rhamnosus GG are the species with the strongest individual evidence; combination products are common, although the Cochrane analysis did not find a clear advantage of multi-strain over single-strain formulations. [7,8]
Doses studied: S. boulardii: 250-500 mg twice daily for the duration of the antibiotic course plus a few days. L. rhamnosus GG: 10-20 billion CFU daily.
Bifidobacterium longum
Moderate evidenceL. rhamnosus and B. longum are commonly bundled in multi-strain probiotic products targeting general gut, immune and (in some trials) mood claims.
Bifidobacterium longum dominates the infant colon and remains a significant component of the adult gut microbiome; it ferments oligosaccharides to short-chain fatty acids (acetate, lactate) that modulate gut pH and act as substrates for downstream butyrate-producing bacteria. Lactobacillus rhamnosus GG occupies different niches, produces antimicrobial peptides, and has the strongest individual evidence base for antibiotic-associated and acute infectious diarrhoea. The combination is mechanistically complementary (different niches, different metabolic outputs) rather than directly synergistic.
Evidence: Goldenberg 2017 (Cochrane CD006095) covers multi-strain probiotic evidence in adults and children. Multi-strain products including B. longum and L. rhamnosus are heavily represented in the trial pool but the meta-analysis did not find a definitive advantage of multi-strain over single-strain formulations for the primary outcome (CDAD prevention). Other endpoints (general gut comfort, immune signalling, mood — see Pinto-Sanchez 2017 for B. longum mood data) have variable individual evidence. [7]
Doses studied: Multi-strain products typically deliver 5-20 billion CFU per strain per day. No definitive clinical-outcome dose-response established.
Bifidobacterium animalis subsp. lactis (BB-12, HN019, DN-173 010)
Moderate evidenceBB-12 + L. rhamnosus GG — the most-evidenced probiotic combination for antibiotic-associated diarrhoea prevention.
BB-12 + LGG combination is supported by Cochrane systematic review for AAD prevention. Mechanism: complementary genus coverage (Bifidobacterium + Lactobacillus); BB-12 adheres to gut mucin; LGG supports gut-barrier integrity.
Evidence: Cochrane review supports BB-12 + LGG combination for AAD prevention. [9]
Doses studied: BB-12 10⁹-10¹⁰ CFU/day + LGG 10⁹-10¹⁰ CFU/day, alongside antibiotic course + 1-2 weeks after.
Kefir (Multi-strain fermented milk)
Limited evidenceKefir flora may include L. rhamnosus species but rarely the trial-grade L. rhamnosus GG strain. For strain-specific clinical claims, capsule supplements with declared trial-grade strain.
Kefir provides broad multi-strain probiotic biomass. Specific clinical evidence (e.g. L. rhamnosus GG for paediatric acute gastroenteritis per Cochrane) requires specific strain identification.
Evidence: Strain-specific evidence in L. rhamnosus GG; kefir-specific evidence weaker.
Doses studied: Kefir 100-300 mL daily as broad-spectrum + L. rhamnosus GG capsule 10⁹-10¹⁰ CFU for specific clinical indication.
Kombucha (Fermented sweetened tea)
Limited evidenceStrain-specific clinical claims require trial-grade strain — kombucha rarely contains L. rhamnosus GG. Capsule supplement for clinical indications.
Generic kombucha biomass + specific-strain capsule for clinical indications.
Evidence: Strain-specific evidence applies to capsule supplements, not generic kombucha.
Doses studied: Kombucha 100-300 mL daily as broad-spectrum + L. rhamnosus GG capsule 10⁹-10¹⁰ CFU for specific clinical indication.
L-Glutamine
Limited evidenceGut-cluster pairing — glutamine intestinal substrate + LGG probiotic colonisation.
Glutamine substrate for enterocytes + colonocytes; LGG probiotic biomass. Different mechanisms; complementary on gut-mucosa axis.
Evidence: Camden lactobacillus-rhamnosus cluster.
Doses studied: 5-10 g/day glutamine + 10⁹-10¹⁰ CFU LGG daily.
Lactobacillus plantarum / Lactiplantibacillus plantarum (299v / CECT 7484/7485)
Limited evidenceMulti-strain Lactobacillus combination — broader genus coverage with overlapping AAD-prevention + paediatric trial bodies.
L. rhamnosus GG + L. plantarum 299v — different strains with overlapping IBS-symptom + AAD-prevention indications. Combination products extend strain coverage.
Evidence: Each component has individual trial body.
Doses studied: 10⁹-10¹⁰ CFU each daily; many UK multi-strain products combine.
Lactobacillus reuteri
Moderate evidenceLactobacillus cluster — most-trialled lactobacillus strains. Both have AAD-prevention + paediatric trial bodies.
L. rhamnosus GG + L. reuteri DSM 17938 — different strains, overlapping AAD-prevention + paediatric-acute-gastroenteritis evidence. Combination products extend strain coverage.
Evidence: Cochrane probiotic-AAD support; Camden lactobacillus-rhamnosus covers detail. [10,11,12]
Doses studied: 10⁹-10¹⁰ CFU each strain daily during antibiotic course + 1-2 weeks after.